Drug Trial Radar · NCT05599191
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
957
Actual
Start
Oct 25, 2022
Primary completion
Dec 17, 2025
Study completion Jun 18, 2026
Sponsor
- Lead sponsor
- Bellus Health Inc. - a GSK companyIndustry
- Sponsor type
- Industry
- First posted
- Oct 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
Conditions
- Cough
- Refractory Chronic Cough
Interventions
BLU-5937Drug
Oral administration of BLU-5937 Tablets
PlaceboDrug
Oral administration of matching placebo for BLU-5937 Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- 24-Hour Cough FrequencyTime frame: Week 12
- Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) up to Week 52Time frame: Up to Week 52
- Number of Participants with Adverse Events of Medical Interest (AEMIs) up to Week 52Time frame: Up to Week 52
- Number of Participants with Study Treatment Discontinuation due to AEs and SAEs up to Week 52Time frame: Up to Week 52
- Number of Participants with AEs and SAEs Leading to Study Withdrawal up to Week 52Time frame: Up to Week 52
- Change from Baseline in Vital Signs: Systolic and Diastolic Blood Pressure (millimeters of mercury [mm Hg]) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Vital Sign: Pulse (beats per minute) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Vital Sign: Respiratory Rate (breaths per minute) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Vital Sign: Body Temperature (degrees Celsius) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Vital Sign: Weight (kilograms [kg]) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Male Reproductive Hormone: Total Testosterone (nanomoles per liter [nmol/L]) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Male Reproductive Hormones: Follicle-Stimulating Hormone [FSH] and Luteinizing Hormone [LH] (international units per liter [IU/L]) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Male Reproductive Hormone: Inhibin B (nanograms per liter [ng/L]) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Hematology Parameter: Red Blood Cell (RBC) Count (10^12 cells per liter) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Hematology Parameters: Hemoglobin and Mean Corpuscular Hemoglobin Concentration (MCHC) (grams per liter [g/L]) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Hematology Parameter: Hematocrit (percentage) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Hematology Parameter: Mean Corpuscular Volume (MCV) (femtoliters [fL]) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Hematology Parameter: Mean Corpuscular Hemoglobin (MCH) (picograms per cell [pg/cell]) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Hematology Parameter: Red Cell Distribution Width (RDW) (percentage) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Hematology Parameters: White Blood Cell (WBC) Count (neutrophils, lymphocytes, monocytes, eosinophils, and basophils) and Platelet Count (10^9 cells per liter) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), and Gamma-Glutamyl Transferase (GGT) (units per liter [U/L]) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Clinical Chemistry Parameters: Alkaline Phosphatase (ALP) and Creatine Kinase (CK) (international units per liter [IU/L]) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Clinical Chemistry Parameters: Total Bilirubin, Direct and Indirect Bilirubin, and Creatinine (micromoles per liter) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Clinical Chemistry Parameters: Sodium, Potassium, Chloride, Calcium, Magnesium, Bicarbonate, Glucose, and Blood Urea Nitrogen (BUN) (millimoles per liter [mmol/L]) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Clinical Chemistry Parameters: Protein and Albumin (grams per liter [g/L]) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Clinical Chemistry Parameter: Estimated Glomerular Filtration Rate (eGFR) (milliliters per minute per 1.73 meters squared [mL/min/1.73 m^2]) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Clinical Chemistry Parameters: Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) (seconds) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in Electrocardiogram (ECG) Value: Heart Rate (beats per minute) at Week 52Time frame: Baseline, Week 52
- Change from Baseline in ECG Value: PR Interval, QT Interval, RR Interval, QRS Interval, and Corrected QT Interval Using Fridericia's Formula (QTcF) (milliseconds) at Week 52Time frame: Baseline, Week 52
Locations
200 sites in 15 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Jasper, Alabama
GSK Investigational Site
Litchfield Park, Arizona
GSK Investigational Site
Scottsdale, Arizona
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Encinitas, California
GSK Investigational Site
Mission Viejo, California
GSK Investigational Site
Paramount, California
GSK Investigational Site
Roseville, California
GSK Investigational Site
Aurora, Colorado
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Clearwater, Florida
GSK Investigational Site
Gainesville, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Lawrenceville, Georgia
GSK Investigational Site
Normal, Illinois
GSK Investigational Site
Oak Lawn, Illinois
GSK Investigational Site
Ames, Iowa
GSK Investigational Site
Iowa City, Iowa
GSK Investigational Site
Kansas City, Kansas
GSK Investigational Site
Topeka, Kansas
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
Crowley, Louisiana
GSK Investigational Site
Shreveport, Louisiana
GSK Investigational Site
Annapolis, Maryland
GSK Investigational Site
North Dartmouth, Massachusetts
GSK Investigational Site
Ann Arbor, Michigan
GSK Investigational Site
Ypsilanti, Michigan
GSK Investigational Site
Columbia, Missouri
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Missoula, Montana
GSK Investigational Site
Jersey City, New Jersey
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Raleigh, North Carolina
GSK Investigational Site
Rocky Mount, North Carolina
Showing 40 of 200 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.